Nebraska Methodist Hospital ( Site 0004) — Omaha, Nebraska

Public research footprint of Nebraska Methodist Hospital ( Site 0004), compiled from the ClinicalTrials.gov public registry.

389

Registered studies

142

Active

Recruiting now

179

Completed

Stopped or withdrawn

Most-studied conditions

Endometrial Clear Cell Adenocarcinoma · EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified · Metastatic Bladder Clear Cell (Glycogen-Rich) Urothelial Carcinoma · Recurrent Platinum-Resistant Fallopian Tube Carcinoma

Recently updated registry entries

NCT04739800 — Comparison of Standard of Care Treatment With a Triplet Combination of Targeted… (Active Not Recruiting)
NCT05112601 — Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR)… (Recruiting)
NCT04267848 — Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy… (Recruiting)

7 more recent registry entries at this facility

Enter your work email to view the full list.

I’d also like to receive occasional marketing emails from Eichor for research sites (optional — unsubscribe anytime).

Work at Nebraska Methodist Hospital ( Site 0004)?

Verify and correct how your facility appears in public registry records — free.

Verify this profile →

Compiled from public registry records (ClinicalTrials.gov) as of August 04, 2026. Counts reflect how this facility appears in registry listings; name variants may exist and are not combined. This page describes public records only and makes no assessment of any facility.